MacroGenics and Takeda Pharmaceutical have entered into an option agreement for pharma deal for the development and commercialization of MGD010.
This product candidate incorporates MacroGenics' proprietary platform for Dual-Affinity Re-Targeting (DART) to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins.
MGD010 is currently in pre-clinical development for the treatment of autoimmune diseases.
MacroGenics will receive an upfront payment of $15 million and Takeda receives an option to obtain an exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a study.
MacroGenics will lead all product development activities until that time.
If Takeda exercises its option, it will assume responsibility for future development and pay MacroGenics an option exercise fee which, when combined with the upfront payment and an early development milestone, will total $33 million.
Assuming successful development and commercialization of MGD010, MacroGenics could receive up to an additional $468.5 million in clinical, regulatory and commercialization milestone payments.
If commercialized, MacroGenics would receive double-digit royalties on any global net sales and has the option to co-promote MGD010 with Takeda in the United States.
Finally, MacroGenics may elect to fund a portion of Phase 3 clinical development in exchange for a North American profit share.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity